EirGenix
EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatme… Read more
EirGenix (6589) - Net Assets
Latest net assets as of June 2025: NT$8.46 Billion TWD
Based on the latest financial reports, EirGenix (6589) has net assets worth NT$8.46 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$10.40 Billion) and total liabilities (NT$1.94 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$8.46 Billion |
| % of Total Assets | 81.35% |
| Annual Growth Rate | 34.79% |
| 5-Year Change | 385.84% |
| 10-Year Change | N/A |
| Growth Volatility | 156.45 |
EirGenix - Net Assets Trend (2017–2024)
This chart illustrates how EirGenix's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EirGenix (2017–2024)
The table below shows the annual net assets of EirGenix from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$9.26 Billion | -7.58% |
| 2023-12-31 | NT$10.02 Billion | -6.23% |
| 2022-12-31 | NT$10.68 Billion | +2.44% |
| 2021-12-31 | NT$10.43 Billion | +447.26% |
| 2020-12-31 | NT$1.91 Billion | -42.28% |
| 2019-12-31 | NT$3.30 Billion | +58.14% |
| 2018-12-31 | NT$2.09 Billion | +82.36% |
| 2017-12-31 | NT$1.14 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to EirGenix's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3780800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$9.96 Billion | 107.54% |
| Total Equity | NT$9.26 Billion | 100.00% |
EirGenix Competitors by Market Cap
The table below lists competitors of EirGenix ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ningbo Ligong Online Monitoring Technology Co Ltd
SHE:002322
|
$386.64 Million |
|
BRBI BR Partners S.A. ADSs
NASDAQ:BRBI
|
$386.65 Million |
|
Bukit Uluwatu Villa Tbk
JK:BUVA
|
$386.79 Million |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
$386.87 Million |
|
Beijing Forever Technology Co Ltd
SHE:300365
|
$386.36 Million |
|
Furuno Electric Co., Ltd.
PINK:FNOEF
|
$386.02 Million |
|
North Long Dragon New Materials Technology Co. Ltd. A
SHE:301357
|
$386.00 Million |
|
Metro Investment Development Co Ltd
SHG:600683
|
$385.96 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EirGenix's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,017,463,000 to 9,258,257,000, a change of -759,206,000 (-7.6%).
- Net loss of 698,344,000 reduced equity.
- Share repurchases of 61,010,000 reduced equity.
- New share issuances of 17,892,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-698.34 Million | -7.54% |
| Share Repurchases | NT$61.01 Million | -0.66% |
| Share Issuances | NT$17.89 Million | +0.19% |
| Other Changes | NT$-17.74 Million | -0.19% |
| Total Change | NT$- | -7.58% |
Book Value vs Market Value Analysis
This analysis compares EirGenix's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.51x to 2.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$10.20 | NT$66.40 | x |
| 2018-12-31 | NT$12.99 | NT$66.40 | x |
| 2019-12-31 | NT$10.16 | NT$66.40 | x |
| 2020-12-31 | NT$9.42 | NT$66.40 | x |
| 2021-12-31 | NT$42.98 | NT$66.40 | x |
| 2022-12-31 | NT$35.23 | NT$66.40 | x |
| 2023-12-31 | NT$32.86 | NT$66.40 | x |
| 2024-12-31 | NT$30.31 | NT$66.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EirGenix utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -69.21%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 1.17x
- Recent ROE (-7.54%) is above the historical average (-19.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -15.27% | -58.70% | 0.18x | 1.48x | NT$-289.34 Million |
| 2018 | -17.62% | -130.32% | 0.09x | 1.43x | NT$-576.56 Million |
| 2019 | -46.41% | -180.83% | 0.14x | 1.84x | NT$-1.05 Billion |
| 2020 | -54.66% | -97.19% | 0.28x | 2.01x | NT$-1.23 Billion |
| 2021 | -0.41% | -2.51% | 0.15x | 1.10x | NT$-1.09 Billion |
| 2022 | -1.08% | -7.80% | 0.13x | 1.11x | NT$-1.18 Billion |
| 2023 | -9.14% | -89.49% | 0.09x | 1.11x | NT$-1.92 Billion |
| 2024 | -7.54% | -69.21% | 0.09x | 1.17x | NT$-1.62 Billion |
Industry Comparison
This section compares EirGenix's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EirGenix (6589) | NT$8.46 Billion | -15.27% | 0.23x | $386.62 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |